Close Menu

NEW YORK – Exact Sciences' stock took a 10 percent tumble on Monday, closing at $108.74 as investors reacted negatively to a study published in PLOS One that called the company's colorectal cancer screening test Cologuard "an inefficient screening option" for the disease.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.